Reference : JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloprolifera...
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/10993/16825
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
English
Gäbler, Karoline mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Behrmann, Iris mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Haan, Claude mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
2013
JAK-STAT
Landes Bioscience
2
3
JAKSTAT
e25025
Yes (verified by ORBilu)
International
2162-3988
[en] The Janus kinase 2 (JAK2) mutant V617F and other JAK mutants are found in patients with myeloproliferative neoplasms and leukemias. Due to their involvement in neoplasia and inflammatory disorders, Janus kinases are promising targets for kinase inhibitor therapy. Several small-molecule compounds are evaluated in clinical trials for myelofibrosis, and ruxolitinib (INCB018424, Jakafi®) was the first Janus kinase inhibitor to receive clinical approval. In this review we provide an overview of JAK2V617F signaling and its inhibition by small-molecule kinase inhibitors. In addition, myeloproliferative neoplasms are discussed regarding the role of JAK2V617F and other mutant proteins of possible relevance. We further give an overview about treatment options with special emphasis on possible combination therapies.
http://hdl.handle.net/10993/16825
10.4161/jkst25025
http://www.landesbioscience.com/journals/jak-stat/article/25025/

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Gäbler-2013-JAKSTAT-review.pdfPublisher postprint2.38 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.